Education
About Us
Working with TipRanks
Follow Us
BridgeBio Pharma Inc (BBIO)
NASDAQ:BBIO
BBIO Stock Chart & Stats
$62.73
-$0.10(-0.35%)
At close: 4:00 PM EST
$62.73
-$0.10(-0.35%)
Day’s Range― - ―
52-Week Range$21.72 - $69.48
Previous CloseN/A
Volume379.31K
Average Volume (3M)2.43M
Market Cap
$12.08B
Enterprise Value$12.03B
Total Cash (Recent Filing)$645.94M
Total Debt (Recent Filing)$8.72M
Price to Earnings (P/E)―
Beta1.05
Next Earnings
Feb 19, 2026EPS Estimate
-0.74Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.95
Shares Outstanding192,708,820
10 Day Avg. Volume3,549,242
30 Day Avg. Volume2,434,073
Financial Highlights & Ratios
PEG Ratio0.35
Price to Book (P/B)-3.50
Price to Sales (P/S)23.01
P/FCF Ratio-9.79
Enterprise Value/Market Cap1.00
Enterprise Value/Revenue34.01
Enterprise Value/Gross Profit35.51
Enterprise Value/Ebitda-17.77
Forecast
1Y Price Target
$81.59Price Target Upside30.07% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering18
EPS Forecast (FY)-3.49
Revenue Forecast (FY)$488.75M
Bulls Say, Bears Say
Bulls Say
New Drug ApplicationsMultiple near- and medium-term catalysts are expected to maintain positive stock price momentum, with new drug applications for ribitol and encaleret planned.
Patient OutcomesAcoramidis has shown superiority to tafamidis in terms of transthyretin stabilization and patient outcomes, including reduced cardiovascular mortality risk.
Revenue GrowthBridgeBio reported top-line revenue totaling $120.7M, surpassing the forecast of $96.8M, driven by strong demand for acoramidis.
Bears Say
Financial PerformanceBridgeBio recorded a net loss of $0.95 per share, wider than the forecasted net loss of $0.87 per share, due to higher-than-expected SG&A spending.
BridgeBio Pharma News
BBIO FAQ
What was BridgeBio Pharma Inc’s price range in the past 12 months?
BridgeBio Pharma Inc lowest stock price was $21.72 and its highest was $69.48 in the past 12 months.
What is BridgeBio Pharma Inc’s market cap?
BridgeBio Pharma Inc’s market cap is $12.08B.
When is BridgeBio Pharma Inc’s upcoming earnings report date?
BridgeBio Pharma Inc’s upcoming earnings report date is Feb 19, 2026 which is in 103 days.
How were BridgeBio Pharma Inc’s earnings last quarter?
BridgeBio Pharma Inc released its earnings results on Oct 29, 2025. The company reported -$0.95 earnings per share for the quarter, missing the consensus estimate of -$0.894 by -$0.056.
Is BridgeBio Pharma Inc overvalued?
According to Wall Street analysts BridgeBio Pharma Inc’s price is currently Undervalued.
Does BridgeBio Pharma Inc pay dividends?
BridgeBio Pharma Inc does not currently pay dividends.
What is BridgeBio Pharma Inc’s EPS estimate?
BridgeBio Pharma Inc’s EPS estimate is -0.74.
How many shares outstanding does BridgeBio Pharma Inc have?
BridgeBio Pharma Inc has 192,708,820 shares outstanding.
What happened to BridgeBio Pharma Inc’s price movement after its last earnings report?
BridgeBio Pharma Inc reported an EPS of -$0.95 in its last earnings report, missing expectations of -$0.894. Following the earnings report the stock price went down -4.878%.
Which hedge fund is a major shareholder of BridgeBio Pharma Inc?
Currently, no hedge funds are holding shares in BBIO
BridgeBio Pharma Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$81.59 (30.07% Upside)
$81.59 (30.07% Upside)
Blogger Sentiment
Bullish
BBIO Sentiment 85%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 1.5M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $10.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▲ 0.8%
Last 30 Days ▼ 1.2%
Last 30 Days ▼ 1.2%
Technicals
SMA
Positive
20 days / 200 days
Momentum
144.94%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
50.12%
Trailing 12-Months
Company Description
BridgeBio Pharma Inc
BridgeBio Pharma (BBIO) is a biotechnology company focused on developing innovative therapeutics for genetic diseases and cancers. The company operates primarily in the pharmaceutical sector, leveraging advanced genetic insights to identify and develop targeted therapies. BridgeBio specializes in creating treatments that address the underlying genetic causes of diseases, with a robust pipeline of product candidates across various stages of clinical development.
BBIO Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call showcased positive developments with successful Phase III trial results and strong financial performance. However, challenges such as market access competition and increased operating expenses were noted.View all BBIO earnings summariesBBIO Stock 12 Month Forecast
Average Price Target
$81.59
▲(30.07% Upside)
Technical Analysis
BioMarin Pharmaceutical
―
Exelixis
―
Ionis Pharmaceuticals
―
Madrigal Pharmaceuticals
―
Moderna
―
Ownership Overview
21.24% Insiders
21.05% Mutual Funds
0.16% Other Institutional Investors
43.05% Public Companies and Individual Investors